☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
triple-negative breast cancer
Roche Presents New P-III Data of Tecentriq in Triple-Negative Breast Cancer at ESMO Virtual Congress 2020
September 21, 2020
Chugai Launches Tecentriq Intravenous Infusion 840mg as an Optimal Formulation to Treat PD-L1+ Triple-Negative Breast Cancer in Ja...
November 28, 2019
Merck Reports Results of Keytruda (pembrolizumab) + Chemotherapy in P-III KEYNOTE-522 Study for Triple-Negative Breast Cancer
July 30, 2019
Roche's Ventana PD-L1 (SP142) Receives FDA's Approval for Identifying Triple-Negative Breast Cancer (TNBC) as CDx
March 11, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.